Drug Profile
Methyl-GBB - Grindeks
Alternative Names: methyl-gamma-butyrobetaine - GrindeksLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Latvian Institute of Organic Synthesis
- Developer Grindeks
- Class Butyric acids; Cardiovascular therapies; Quaternary ammonium compounds; Small molecules
- Mechanism of Action Gamma-butyrobetaine dioxygenase inhibitors; Organic cation transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Cardiovascular-disorders in Latvia (Parenteral)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Cardiovascular-disorders in Latvia (PO)
- 11 Mar 2020 Methyl-GBB - Grindeks is available for licensing as of 09 Mar 2020